51
|
Garypidou V, Perifanis V, Tziomalos K, Theodoridou S. Cardiac Toxicity During Rituximab Administration. Leuk Lymphoma 2009; 45:203-4. [PMID: 15061224 DOI: 10.1080/10428190310001607160] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
MESH Headings
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Heart Diseases/chemically induced
- Heart Diseases/complications
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/complications
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Male
- Rituximab
Collapse
|
52
|
Athyros VG, Hatzitolios A, Karagiannis A, Didangelos TP, Iliadis F, Dolgyras S, Vosnakidis T, Vasiliadis P, Malias I, Tziomalos K, Samouilidou M, Mikhailidis DP. Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. Curr Med Res Opin 2009; 25:1931-40. [PMID: 19558210 DOI: 10.1185/03007990903073035] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
AIM To assess the efficacy of a strategy to improve vascular risk management in patients with type 2 diabetes mellitus (T2DM). METHODS This was a pilot best practice implementation enhancement programme that enrolled 578 patients with T2DM. A baseline visit was followed by a concerted effort from previously trained physicians to improve adherence to lifestyle advice and optimise drug treatment for all vascular risk factors. The patients were followed-up for 6 months. The UKPDS risk engine was used to estimate vascular risk in patients without established coronary heart disease (CHD) (n = 279). RESULTS There was an improvement in compliance to lifestyle measures and increased prescription of evidence-based medication. In patients without established CHD there was a 37% reduction in estimated risk for CHD, 44% for fatal CHD, 10% for stroke and 25% for fatal stroke (p < or = 0.003 for all comparisons vs. baseline). There was also a substantial increase in the proportion of patients with established CHD who achieved their vascular risk factor targets. CONCLUSIONS This is the first study to increase the adherence to multiple interventions in patients with T2DM in both primary care and hospital settings. Education of physicians and patients, distribution of guidelines/brochures, and the completion of a one-page form, motivated both physicians and patients to achieve multiple vascular risk factor goals.
Collapse
|
53
|
Tsantilas D, Hatzitolios AI, Tziomalos K, Papadimitriou DK. Buflomedil: potential new indications for an old agent. INT ANGIOL 2009; 28:170-174. [PMID: 19174750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Our understanding of vascular pathophysiology has significantly improved during the past two decades. Patients with type 2 diabetes mellitus have an increased vascular risk and a series of modifiable risk factors play a crucial role in the atherosclerotic process. The microvascular dysfunction in diabetes results in increased vascular permeability and impaired regulation of blood flow and vascular tone. These changes culminate in nephropathy, retinopathy and neuropathy and probably contribute to the increase vascular morbidity and mortality in this population. Moreover, studies in the skin microvasculature suggest that this microvascular dysfunction contributes significantly to the pathogenesis of diabetic foot. Several studies showed a beneficial effect of vasoactive drugs, including buflomedil, in non-diabetic patients. However, it remains to be established whether these drugs could also be beneficial in the diabetic population, especially in the early stages of diabetes.
Collapse
|
54
|
Hatzitolios A, Athyros V, Karagiannis A, Savopoulos C, Charalambous C, Kyriakidis G, Milidis T, Papathanakis C, Bitli A, Vogiatsis I, Ntaios G, Katsiki N, Symeonidis A, Tziomalos K, Mikhailidis D. Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. Int J Cardiol 2009; 134:322-9. [DOI: 10.1016/j.ijcard.2009.02.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2008] [Revised: 11/21/2008] [Accepted: 02/06/2009] [Indexed: 11/15/2022]
|
55
|
Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 2009; 20:197-207. [PMID: 18509713 DOI: 10.1007/s00198-008-0648-5] [Citation(s) in RCA: 119] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2008] [Accepted: 04/30/2008] [Indexed: 11/26/2022]
Abstract
Osteoporosis and atherosclerosis, two multifactorial and degenerative entities, are major public health problems. These diseases accompany the aging process and share common risk factors. Furthermore, several common pathophysiological factors have been suggested. These include similar molecular pathways involving bone and vascular mineralization, estrogen deficiency, parathyroid hormone, homocysteine, lipid oxidation products, inflammatory process, as well as vitamin D and K. Moreover, the use of statins, biphosphonates, beta-blockers and experimental dual-purpose therapies based on the biological linkage of the above entities may simultaneously benefit bone loss and vascular disease. This review considers a potential link between osteoporosis and atherosclerosis beyond aging. These common factors may lead to appropriate treatment strategies.
Collapse
|
56
|
Krassas GE, Papadopoulou F, Tziomalos K, Zeginiadou T, Pontikides N. Hypothyroidism has an adverse effect on human spermatogenesis: a prospective, controlled study. Thyroid 2008; 18:1255-9. [PMID: 19012472 DOI: 10.1089/thy.2008.0257] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND Abnormalities of spermatogenesis are associated with numerous diseases and aging. The objective of this study was to investigate the impact of hypothyroidism on human spermatogenesis and different sperm function tests. METHODS Twenty-five hypothyroid men and 15 normal individuals were investigated. Semen analysis, fructose and acid phosphatase measurements, teratozoospermia index (TZI), and acridine orange test were determined before and 6-9 months after the initiation of treatment with levothyroxine. RESULTS Morphology is the only sperm parameter that differs significantly between hypothyroid patients and controls (p < 0.0001). After treatment, morphology improved significantly (p < 0.001). Motility was also decreased before treatment in comparison with controls, and improved after treatment. However, the difference was not significant. TZI correlated with free thyroxine. CONCLUSIONS Hypothyroidism has an adverse effect on human spermatogenesis. Morphology is the only sperm parameter that is significantly affected. Motility may also be affected, but further studies regarding this are needed. Screening for thyroid dysfunction in males who present with a defect in spermatogenesis is strongly recommended, and if hypothyroidism is noted, the response to thyroid hormone should be evaluated before initiating other treatments.
Collapse
|
57
|
Tziomalos K, Tziomalos K, Sivanadarajah N, Mikhailidis DP, Boumpas DT, Seifalian AM. Increased risk of vascular events in systemic lupus erythematosus: is arterial stiffness a predictor of vascular risk? Clin Exp Rheumatol 2008; 26:1134-1145. [PMID: 19210887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Patients with systemic lupus erythematosus (SLE) have an increased vascular morbidity and mortality. Several established vascular risk factors are more prevalent in this population but cannot fully explain the reported excess atherosclerotic burden. Emerging vascular risk factors may also contribute to the increased vascular risk in these patients although the evidence is limited and often conflicting. SLE-specific risk factors also play a role in the pathogenesis of atherosclerosis.Given the multifactorial aetiology of vascular disease in SLE, an integrated index of risk could be useful in the management of these patients. Arterial stiffness possibly represents such an index and accumulating data suggest an increased prevalence of arterial stiffness in SLE. Many factors play a role in the loss of arterial elasticity in this population, including both emerging and established vascular risk factors. Arterial stiffness may emerge as a useful index for risk stratification in SLE and has the potential to guide therapeutic decisions in these patients.
Collapse
|
58
|
Athyros VG, Kakafika A, Tziomalos K, Karagiannis A, Mikhailidis D. CORONA, Statins, and Heart Failure: Who Lost the Crown? Angiology 2008. [DOI: 10.1177/0003319708322391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
59
|
Baltatzi M, Hatzitolios A, Tziomalos K, Iliadis F, Zamboulis C. Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension. Int J Clin Pract 2008; 62:1432-40. [PMID: 18793378 DOI: 10.1111/j.1742-1241.2008.01823.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
AIM Obesity and hypertension frequently coexist and both represent important risk factors for cardiovascular disease. The mechanisms implicated in the regulation of food intake have not been completely elucidated. Recent data suggests that peripheral and central neuropeptides play an important role in the maintenance of energy balance. More specifically, leptin, neuropeptide Y (NPY) and alpha-melanocyte-stimulating hormone (a-MSH) appear to be implicated in the pathogenesis of obesity and also contribute to the development of hypertension in obesity. METHODS Analysis of the pertinent bibliography published in PubMed database. RESULTS Leptin is produced in the adipose tissue directly correlated with fat tissue mass. Leptin acts on two distinct neural populations in the hypothalamus: the first expresses the orexigenic peptides NPY and agouti-related protein (AgRP), the second pro-opiomelanocortin (POMC). The activation of POMC neurons increases the production of the anorexigenic hormone a-MSH and inhibits the release of NPY and AgRP. In addition, the hypothalamus integrates the neuroendocrine systems with the autonomic nervous system and controls the activity of the latter. Stimulation of hypothalamic nuclei elicits sympathetic responses including blood pressure elevation. Both NPY and a-MSH appears to be implicated in the hypothalamic regulation of sympathetic nervous system (SNS) activity. CONCLUSION Alterations in leptin, NPY and a-MSH are frequently observed in obesity and might stimulate SNS activity, contributing to the development of hypertension in obese patients. These neuropeptides might provide a pathophysiologic link between excess weight and hypertension. However, more research is needed before the pharmacologic manipulation of these complex neuroendocrine systems can be applied in the treatment of obesity and hypertension.
Collapse
|
60
|
Krassas GE, Tziomalos K, Papadopoulou F, Pontikides N, Perros P. Erectile dysfunction in patients with hyper- and hypothyroidism: how common and should we treat? J Clin Endocrinol Metab 2008; 93:1815-9. [PMID: 18270255 DOI: 10.1210/jc.2007-2259] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Erectile dysfunction (ED) is associated with numerous diseases and aging. OBJECTIVE The objective of the study was to investigate the impact of hyper- and hypothyroidism on male sexual health by using the Sexual Health Inventory for Males (SHIM). DESIGN Seventy-one men, 27 hyper- and 44 hypothyroid and a similar number of controls were included in the study. A validated SHIM 5-item questionnaire was administered to all participants. Patients were asked to respond before and a year after initiation of treatment for thyroid dysfunction. A score between 25 and 22 is considered normal, between 21 and 11 diagnostic of mild to moderately severe ED, and 10 or less diagnostic of severe ED. RESULTS Fifty-six men with thyroid dysfunction (78.9%; 19 hyperthyroid and 37 hypothyroid) had a SHIM score of 21 or less, compared with 24 controls (33.8%) (P < 0.0001). Twenty-one patients with ED (37.5%) had SHIM scores 10 or less, indicative of severe ED, compared with six controls (25%) (P < 0.01). ED was more prevalent in patients with hyperthyroidism and hypothyroidism, compared with controls (P < 0.001 and P < 0.0001, respectively). Positive correlation was found between SHIM scores and serum free T(4) (r = 0.413, P = 0.005) and negative for TSH (r = -0.669, P < 0.001). After treatment a significant increase of SHIM scores was noted in both hyperthyroid (P < 0.0001) and hypothyroid (P < 0.0001) patients. CONCLUSIONS ED is extremely common in males with dysthyroidism. Treatment of the latter restores erectile function. Screening for thyroid dysfunction in men presenting with ED is recommended, whereas specific treatment for ED should be postponed in such patients for at least 6 months after achieving euthyroidism because the latter might be responsible for ED.
Collapse
|
61
|
Karagiannis A, Tziomalos K, Mikhailidis D, Semertzidis P, Kakafika A, Pagourelias E, Kountana E, Athyros V. SEASONAL VARIATION IN THE OCCURRENCE OF STROKE IN NORTHERN GREECE: A 10 YEAR STUDY IN 8,204 PATIENTS. ATHEROSCLEROSIS SUPP 2008. [DOI: 10.1016/s1567-5688(08)70990-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
62
|
Tziomalos K, Athyros V, Mikhailidis D, Tziomalos K, Athyros V, Mikhailidis D. Fish Oils and Vascular Disease Prevention: An Update. Curr Med Chem 2007; 14:2622-8. [DOI: 10.2174/092986707782023307] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
63
|
Athyros V, Liberopoulos E, Mikhailidis D, Papageorgiou A, Ganotakis E, Tziomalos K, Kakafika A, Karagiannis A, Hatziolios A, Elisaf M. PO20-609 ASSOCIATION OF DRINKING PATTERN WITH THE PREVALENCE OF METABOLIC SYNDROME, DIABETES, CORONARY HEART DISEASE, STROKE AND PERIPHERAL ARTERIAL DISEASE. ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71619-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
64
|
Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F. Persistent effect of zoledronic acid in Paget's disease. Clin Exp Rheumatol 2007; 25:464-6. [PMID: 17631747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Paget's bone disease is a disorder in which bone regions with high turnover are replaced by new, vascular, but disorganized and immature bone with excessive fibrosis, high tendency of deformity and diminished mechanical resistance. Treatment aims at the suppression of osteoclast activity and is achieved with bisphosphonates, which represent the treatment of choice for Paget's disease. Zoledronic acid, a relatively new member of this class, normalizes alkaline phosphatase in the majority of patients and has a favorable safety profile. We report the case of an asymptomatic patient who was diagnosed with Paget's disease based on typical biochemical, radiological and histological findings and was treated with a single intravenous infusion of 4 mg of zoledronic acid. No side effects were observed. Alkaline phosphatase levels normalized within four months. At the last follow up examination, three years after treatment, the patient remains asymptomatic, without significant changes in radiology imaging, and alkaline phosphatase levels are still within the normal range. In conclusion, zoledronic acid, apart from being safe and effective in Paget's disease, also appears to be able to achieve significantly prolonged remissions.
Collapse
|
65
|
Katsinelos P, Tziomalos K, Chatzimavroudis G, Vasiliadis T, Katsinelos T, Pilpilidis I, Triantafillidis I, Paroutoglou G, Papaziogas B. Eradication therapy in Helicobacter pylori-positive patients with halitosis: long-term outcome. Med Princ Pract 2007; 16:119-23. [PMID: 17303947 DOI: 10.1159/000098364] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2005] [Accepted: 06/03/2006] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVE The aim of this study was to investigate the incidence and long-term outcome of halitosis before and after eradication therapy in patients with functional dyspepsia and Helicobacter pylori infection. SUBJECTS AND METHODS Halitosis and dyspepsia-related symptoms were investigated by way of a questionnaire. Only patients with functional dyspepsia, H. pylori infection and no histological evidence of atrophy were included in the study. A total of 18 patients fulfilled these criteria and completed the study. Four to six weeks after the end of eradication treatment, endoscopy or [(13)C] breath test was performed to check for H. pylori in the gastric mucosa. Halitosis and dyspeptic symptoms were re-evaluated during and at the end of follow-up. RESULTS H. pylori infection was eradicated in all patients, in the 14/18 patients (77.8%) with triple drug therapy, and the 4/18 patients (22.2%) with quadruple drug therapy. During the follow-up period (mean 55.8 +/- 21.3 months (range 6-108 months)) resolution of halitosis was observed in 16/18 patients (88.9%), while 2 patients (11.1%) (p < 0.001) continued to present with halitosis. Also, eradication therapy resulted in statistically significant relief of all dyspeptic symptoms, except bloating. CONCLUSION Eradication of H. pylori in patients with functional dyspepsia and halitosis results in sustained resolution of halitosis during long-term follow-up in the majority of cases. This finding supports the existence of a link between H. pylori infection and halitosis and suggests that H. pylori eradication might be considered in patients with halitosis.
Collapse
|
66
|
Vakalopoulou S, Rizopoulou D, Zafiriadou E, Perifanis V, Tziomalos K, Lefkou E, Hill M, Dolan G, Garipidou V. Management of acute bleeding in a patient with congenital afibrinogenaemia. Haemophilia 2006; 12:676-8. [PMID: 17083521 DOI: 10.1111/j.1365-2516.2006.01340.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Congenital afibrinogenaemia is a rare bleeding disorder characterized by absence of fibrinogen and varying bleeding tendency. Treatment with fibrinogen concentrates is considered to be the best choice for afibrinogenaemic patients who experience bleeding. We report the case of a 22-year-old Greek patient who presented with large muscular haematomas and was treated with fibrinogen concentrates. The efficacy of this treatment and the problems that arose during his hospitalization are being discussed.
Collapse
|
67
|
Karagiannis A, Pyrpasopoulou A, Tziomalos K, Florentin M, Athyros V. Angioedema may not be a class side-effect of the angiotensin-converting-enzyme inhibitors. QJM 2006; 99:197-8. [PMID: 16495301 DOI: 10.1093/qjmed/hcl022] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
68
|
Athyros V, Liberopoulos E, Mikhailidis D, Ganotakis E, Tziomalos K, Kakafika A, Kargiannis A, Lambropoulos S, Elisaf M. Mo-P1:78 The effect of drinking pattern and type of alcoholic beverage on the prevalence of metabolic syndrome, diabetes, coronary heart disease and stroke in a Mediterranean cohort. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)80213-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
69
|
Karagiannis A, Semertzidis P, Tziomalos K, Kakafika A, Sileli M, Kountana E, Athyros V, Zamboulis C. Mo-P4:286 Seasonal variation in the occurrence of stroke in Northern Greece. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)80419-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
70
|
Karagiannis A, Tziomalos K, Dona K, Pyrpasopoulou A, Kartali N, Athyros V, Zamboulis C. Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient. QJM 2005; 98:913-5. [PMID: 16299060 DOI: 10.1093/qjmed/hci143] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
71
|
Athyros V, Mikhailidis D, Papageorgiou A, Didangelos T, Peletidou A, Kleta D, Karagiannis A, Kakafika A, Tziomalos K, Elisaf M. T03-P-002 Targeting cardiovascular risk plunge in metabolic syndrome: The targets study. ATHEROSCLEROSIS SUPP 2005. [DOI: 10.1016/s1567-5688(05)80570-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
72
|
Vassiliadis T, Nikolaidis N, Giouleme O, Tziomalos K, Grammatikos N, Patsiaoura K, Zezos P, Gkisakis D, Theodoropoulos K, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005; 21:531-7. [PMID: 15740536 DOI: 10.1111/j.1365-2036.2005.02388.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Long-term treatment with lamivudine is required to control viral replication in patients with hepatitis B e antigen-negative chronic hepatitis B, but is associated with a high rate of viral resistance. The role of adefovir dipivoxil in these patients has not been definitively evaluated. AIM To address the role of adefovir in the management of patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. METHODS Patients were assigned to receive adefovir 10 mg once daily plus ongoing lamivudine 100 mg once daily for 52 weeks. The primary end point was reduction in serum hepatitis B virus DNA level (hepatitis B virus DNA response). Secondary end points included the proportion of patients with undetectable hepatitis B virus DNA at week 52 (complete virological response) and the percentage of patients with normalization of alanine transferase level at week 52 (biochemical response). RESULTS A total of 49 consecutive patients were enrolled in this study. After 52 weeks of treatment, all patients had an hepatitis B virus DNA response and 57.1% had complete virological response. Biochemical response occurred in 75.6% of patients. CONCLUSIONS Administration of adefovir in patients with lamivudine-resistant chronic hepatitis B results in significant suppression of viral replication. Nevertheless, continuous therapy will probably be needed in order to maintain remission in these patients.
Collapse
|
73
|
Garipidou V, Vakalopoulou S, Zafiriadou E, Kaloutsi V, Tziomalos K, Perifanis V. Uncommon manifestation of bleomycin-induced pulmonary toxicity in a patient with Hodgkin's disease. Ann Oncol 2005; 16:514-5. [PMID: 15668264 DOI: 10.1093/annonc/mdi073] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
|
74
|
Krikis N, Tziomalos K, Perifanis V, Vakalopoulou S, Karagiannis A, Garipidou V, Harsoulis F. Treatment of recurrent gastrointestinal haemorrhage in a patient with von Willebrand's disease with octreotide LAR and propranolol. Gut 2005; 54:171-2. [PMID: 15591529 PMCID: PMC1774363 DOI: 10.1136/gut.2004.049031] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
75
|
Tziomalos K, Krikis N, Karagiannis A, Perifanis V, Rizopoulou D, Georgopoulou V, Harsoulis F. Treatment of idiopathic retroperitoneal fibrosis with combined administration of corticosteroids and tamoxifen. Clin Nephrol 2004; 62:74-6. [PMID: 15267020 DOI: 10.5414/cnp62074] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|